First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication
Businesswire·2026-10-19 17:30

文章核心观点 - 武田制药公布VERDICT研究新数据 显示静脉注射ENTYVIO治疗成人患者以实现无皮质类固醇疾病清除相比仅实现无皮质类固醇症状缓解 可显著延长首次溃疡性结肠炎相关并发症发生时间 [1] - 风险比0.33 95%置信区间0.17-0.67 P值等于0.0014 溃疡性结肠炎并发症风险降低近70% [1] 研究数据总结 - 研究名称为VERDICT 注册号NCT04259138 [1] - 治疗药物为静脉注射ENTYVIO 通用名vedolizumab [1] - 研究人群为成人溃疡性结肠炎患者 [1] - 主要终点为首次溃疡性结肠炎相关并发症发生时间 [1] - 风险比为0.33 95%置信区间为0.17至0.67 P值为0.0014 [1] - 溃疡性结肠炎并发症风险降低近70% [1]

First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication - Reportify